IP Library Granted Patent US 8,846,771
Granted Patent B2
US 8,846,771 · App. 13/649,987 · Granted Sep 30, 2014

Compositions and methods of delivery of pharmacological agents

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,846,771
App. No.
13/649,987
Granted
Sep 30, 2014
Kind
B2
Abstract

The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.

Claims (12)

1. A method of treating bladder cancer in a human individual, comprising injecting into the individual an effective amount of a pharmaceutical composition comprising paclitaxel and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises albumin, wherein the albumin and the paclitaxel in the composition are formulated as particles, wherein the particles in the composition have a particle size of less than about 200 nm, and wherein the weight ratio of albumin to paclitaxel in the composition is about 1:1 to about 9:1.

2. The method of claim 1 , wherein the albumin is human serum albumin.

3. The method of claim 1 , wherein the ratio (w/w) of the albumin to the paclitaxel in the pharmaceutical composition is 1:1 to 9:1.

4. The method of claim 1 , wherein the ratio (w/w) of the albumin to the paclitaxel in the pharmaceutical composition is about 9:1.

5. The method of claim 2 , wherein the ratio (w/w) of the albumin to the paclitaxel in the pharmaceutical composition is 1:1 to 9:1.

6. The method of claim 2 , wherein the ratio (w/w) of the albumin to the paclitaxel in the pharmaceutical composition is about 9:1.

7. The method of claim 1 , wherein the pharmaceutical composition is injected intravenously.

8. The method of claim 2 , wherein the pharmaceutical composition is injected intravenously.

9. The method of claim 3 , wherein the pharmaceutical composition is injected intravenously.

10. The method of claim 4 , wherein the pharmaceutical composition is injected intravenously.

11. The method of claim 5 , wherein the pharmaceutical composition is injected intravenously.

12. The method of claim 6 , wherein the pharmaceutical composition is injected intravenously.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2014
From: DESAI, NEIL P.; YANG, ANDREW; DE, TAPAS; CI, SHERRY XIAOPEI; SOON-SHIONG, PATRICK; TRIEU, VUONG; GRIM, BRIDGET BEALS; YAO, QIANG
To: AMERICAN BIOSCIENCE, INC.
Reel/Frame 033593/0542 →
MERGER Recorded Aug 22, 2014
From: AMERICAN PHARMACEUTICAL PARTNERS, INC.
To: ABRAXIS BIOSCIENCE, INC.
Reel/Frame 033593/0612 →
MERGER Recorded Aug 22, 2014
From: ABRAXIS BIOSCIENCE, INC.
To: ABRAXIS BIOSCIENCE, LLC
Reel/Frame 033593/0643 →